AZN · AstraZeneca PLC
Price
Snapshot
50 fields · last close| Market Cap | $186.6B |
| P/E | 23.65 |
| Float | 1.50B |
| Beta | 1.38 |
| Volatility | 34.5% |
| Exchange | LSE |
| Sector | Pharmaceuticals |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 76.3 |
| Price | 156.90 |
| Change | +0.00% |
| Prev Close | 156.90 |
| Open | 158.46 |
| Day Low | 156.41 |
| Day High | 158.79 |
| Avg Vol | 2 |
| Avg $ Vol | $262.5M |
| 52W High | 15,730.00 |
| 52W Low | 155.62 |
| 52W Pos | 0.0% |
| From High | −99.00% |
| From Low | +0.82% |
| Max DD 1Y | −25.71% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −3.67% |
| SMA 50 | −3.94% |
| SMA 200 | −13.84% |
| RSI (14) | 37.9 |
| Vol 30D | 22.6% |
| Vol 90D | 31.7% |
| 1Y Range | 156–15,730 |
| Daily bars | 900 |
| Perf Week | −5.81% |
| Perf Month | −2.93% |
| Perf Quarter | −17.49% |
| Perf Half Y | −22.90% |
| Perf Year | −7.01% |
| Perf YTD | −14.33% |
| Prev Day | +0.00% |
| Clavix | B+ |
| Debt / Eq | 0.61 |
| Curr Ratio | 0.94 |
| Int Cover | 10.1× |
| FCF Margin | 12.5% |
| Rev Growth | +6.4% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 8 / 14 |
Clavix risk grade
regraded every trading dayAZN grades B+, 76.3 of 100. Steadiest on Macro Resilience (65), most exposed on News Sentiment (23, weak). 0 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 8 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| AZN | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.38 | 0.42 |
| Volatilityannualized | 34.5% | 10.6% |
| Max drawdown, past yearworst peak-to-trough fall | −25.7% | — |
| Typical daily movemedian absolute daily change | 1.04% | — |
| Days beyond ±3%of the last 252 sessions | 15 (6%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| AZN | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.38 | 0.42 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Low 67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| AZN | |
|---|---|
| 1 week | −5.8% |
| 1 month | −2.9% |
| Year to date | −14.3% |
| 1 year | −7.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| AZN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 17 Sep |
| Average score0 most bearish, 100 most bullish | 70 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 1 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 1 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| AZN | |
|---|---|
| Revenue growthyear over year | +6.4% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openAstraZeneca, Daiichi Sankyo and Summit Therapeutics announced clinical collaboration agreements to test Summit's drug ivonescimab combined with AstraZeneca's cancer drugs Datroway and sonesitatug vedotin across multiple tumor types, starting with a planned late-stage trial in first-line triple-negative breast cancer. AstraZeneca also made an approximately $2 billion equity investment in Summit via convertible preferred stock.
AstraZeneca's stock moved lower as its Datroway drug combination advanced into Phase 3 clinical trials, with three partners agreeing to share trial costs while each keeping separate development and commercial rights.
AstraZeneca is partnering with Daiichi Sankyo and Summit Therapeutics to test ivonescimab combined with Datroway in a planned Phase III trial for first-line triple-negative breast cancer, with all three companies sharing costs.
Summit Therapeutics is partnering with Daiichi Sankyo and AstraZeneca on a Phase 3 clinical trial testing its drug Ivonescimab in combination with Datroway as a first-line treatment for triple-negative breast cancer (an aggressive breast cancer with few treatment options). Summit's CEO called the collaboration an 'important expansion' of the program.
AstraZeneca and Daiichi Sankyo are teaming up with Summit Therapeutics to run a clinical trial combining Summit's drug ivonescimab with AstraZeneca and Daiichi's drug Datroway, starting with a late-stage (Phase III) study in patients with triple-negative breast cancer who haven't been treated before. The three companies will share the cost of the trial, but each keeps full control over developing and selling its own medicine.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc | A- | $158.5B | 36.57 | 0.31 | Compare |
| BMY | Bristol-Myers Squibb Co | B+ | $124.9B | 13.46 | 0.19 | Compare |
| MRK | Merck & Co Inc | B+ | $356.0B | 112.20 | 0.12 | Compare |
| JNJ | Johnson & Johnson | A- | $617.0B | 29.33 | 0.20 | Compare |
| RPRX | Royalty Pharma PLC | A | $32.87B | 40.33 | 0.39 | Compare |
| LLY | Eli Lilly and Co | B | $1.08T | 40.28 | 0.42 | Compare |
| ZTS | Zoetis Inc | B | $31.87B | 11.22 | 0.71 | Compare |
| VTRS | Viatris Inc | B+ | $20.35B | — | 0.90 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.